 (EHIT I), weekly surveillance
(EHIT II), or consideration of antiplatelet vs anticoagulant
therapy (high-risk patients with EHIT II), these should be
rarely encountered in the absence of routine ultrasound
surveillance. ARTE III and IV are presumably more likely
to be symptomatic and to be suspected based on
accepted clinical indications. Although it is not entirely
clear that the natural history of ARTE III to IV is the same
as